Case Studies

Developing scenario-based 5-year commercial assessment across Canada, France, Germany, the UK and the US

01/01/2023

Author:

Sarah Bailey
About the Author

Article Tags

Chemotherapy HTA HTA Process Oncology Pricing

Share this article

Related articles

Articles
30.03.2026
From Evidence to Negotiation: Succeeding Under Ita...

From 1 April 2026, AIFA’s updated HTA guidelines will come into effect, making ...

Read more
Articles
30.03.2026
TrumpRx in Focus: Assessing the Implications for ...

Our previous article explored how TrumpRx might influence drug pricing in the US, the potential ...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.

Talk to an expert

Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.​

Get in touch